Pallini, Greece

Aggelos Karatzas

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 3 EPO patents. Top assignee: Expermed S.a.. Active years: 2017.


% Patents Active = 100.0


 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Aggelos Karatzas: Innovator in Sublingual Pharmaceutical Composition

Introduction

Aggelos Karatzas is a notable inventor based in Pallini Attikis, Greece. He has made significant contributions to the field of pharmaceuticals, particularly in the development of sublingual compositions. His work focuses on enhancing the delivery and effectiveness of antihistamine agents.

Latest Patents

Aggelos Karatzas holds a patent for a sublingual pharmaceutical composition containing an antihistamine agent. The patent, titled "Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof," describes a stable pharmaceutical composition for sublingual administration. This composition includes a therapeutically effective quantity of an antihistamine agent, specifically Dimenhydrinate, along with a process for its preparation. He has 1 patent to his name.

Career Highlights

Aggelos Karatzas is associated with Expermed S.A., where he applies his expertise in pharmaceutical innovations. His work at the company emphasizes the importance of developing effective drug delivery systems that can improve patient outcomes.

Collaborations

Some of his notable coworkers include Evangelos Karavas and Efthimios Koutris. Their collaboration contributes to the advancement of research and development in the pharmaceutical sector.

Conclusion

Aggelos Karatzas is a dedicated inventor whose work in sublingual pharmaceutical compositions showcases his commitment to improving healthcare solutions. His innovative approach continues to influence the field of pharmaceuticals positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…